Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
-
Biomed. Pharmacother. · Nov 2018
CXCL9 promotes the progression of diffuse large B-cell lymphoma through up-regulating β-catenin.
CXC chemokine ligand 9, a member of "cytokine milieu", makes up the microenvironment of lymphoma and plays an important role in the occurrence and development of lymphoma. However, the role of CXC chemokine ligand 9 and its underlying mechanism remains largely unknown in the progression of diffuse large B-cell lymphoma. Wnt/ β -catenin signaling is reported to play an important role in diffuse large B-cell lymphoma, and the overexpression and nuclear accentuation of β-catenin in diffuse large B-cell lymphoma patients' tissues were closely associated with the advanced clinical staging. ⋯ Up-regulation of CXC chemokine ligand 9 promoted the viability and migration and repressed the apoptosis of OCI-Ly8 cells, as well as increased β-catenin expression and translocated it from cytoplasm to nuclear, while these effects were abolished when knockdown β-catenin. In conclusion, this work reveals that CXC chemokine ligand 9 promotes the progression of diffuse large B-cell lymphoma in a β-catenin-dependent manner. Our study provides evidence for the mechanism by which CXC chemokine ligand 9 may function as an oncogene and the potential of serving CXC chemokine ligand 9 as a therapeutic target for diffuse large B-cell lymphoma.
-
Biomed. Pharmacother. · Nov 2018
Analgesic effects of TLR4/NF-κB signaling pathway inhibition on chronic neuropathic pain in rats following chronic constriction injury of the sciatic nerve.
Chronic neuropathic pain (CNP) is attributed to a lesion or disease of the somatosensory system, may be derived from the peripheral and central system. Recent study revealed that spinal cord stimulation attenuated CNP by inhibiting TLR4/NF-κB signaling pathway. The present study focuses on the potential analgesic effects of TLR4/NF-κB signaling pathway on CNP in a rat model of chronic constriction injury (CCI). ⋯ Collectively, this study defines the role of TLR4 and NF-κB, and inhibition of TLR4/NF-κB signaling pathway might contribute to the alleviation of CNP and improvement of MWT and TWL in a rat model of CCI. Additionally, the results obtained from the study provided a promising basis that could aid as an experimental basis for the potential treatment of TLR4/NF-κB signaling pathway.
-
Biomed. Pharmacother. · Nov 2018
LINC01116 targets miR-520a-3p and affects IL6R to promote the proliferation and migration of osteosarcoma cells through the Jak-stat signaling pathway.
The purpose of this study was to find out the important lncRNA-miRNA-mRNA axis and pathway in osteosarcoma (OS) through bioinformatics analysis and verify the biological functions of lncRNA/miRNA/mRNA in OS through in vitro and in vivo assays. ⋯ LINC01116 up-regulated IL6R in OS through targeting miR-520a-3p, thus activating the Jak-stat signaling pathway and promoting the progression of OS.
-
Biomed. Pharmacother. · Nov 2018
Long non-coding RNA SNHG5 sponges miR-26a to promote the tumorigenesis of osteosarcoma by targeting ROCK1.
Osteosarcoma (OS) is one of the most common invasive malignancies of the bone. The long non-coding RNA (lncRNA) SNHG5 (small nucleolar RNA host gene 5) has been consistently shown to be involved in many cancers, although its precise function in osteosarcoma remains poorly understood. In this study, we investigated the role of SNHG5 in OS progression and the underlying mechanism. ⋯ SNHG5 acts as an oncogene in OS via the SNHG5-miR-26a-ROCK1 axis and is therefore a potential novel therapeutic target for OS treatment.
-
Biomed. Pharmacother. · Nov 2018
Targeting of TRX2 by miR-330-3p in melanoma inhibits proliferation.
This study is intended to identify the key gene from gene expression profile and validate its role and regulatory mechanism in melanoma. ⋯ Inhibiting TPX2 by miR-330-3p suppresses the proliferation of melanoma cell lines. miR-330-3p/TPX2 pathway could be a potential therapeutic target in melanoma.